scholarly journals International consensus on methodological issues in standardization of fecal calprotectin measurement in inflammatory bowel diseases

2021 ◽  
Author(s):  
Ferdinando D'Amico ◽  
David T. Rubin ◽  
Paulo Gustavo Kotze ◽  
Fernando Magro ◽  
Britta Siegmund ◽  
...  
Keyword(s):  
Inflammatory Bowel Diseases ◽  
Fecal Calprotectin ◽  
Methodological Issues ◽  
International Consensus ◽  
Bowel Diseases ◽  
Inflammatory Bowel

scholarly journals FECAL CALPROTECTIN: levels for the ethiological diagnosis in Brazilian patients with gastrointestinal symptoms

2015 ◽  
Vol 52 (1) ◽  
pp. 50-54 ◽  
Author(s):  
Lorete Maria da Silva KOTZE ◽  
Renato Mitsunori NISIHARA ◽  
Sandra Beatriz MARION ◽  
Murilo Franco CAVASSANI ◽  
Paulo Gustavo KOTZE
Keyword(s):  
Ulcerative Colitis ◽  
Irritable Bowel Syndrome ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Inflammatory Bowel Diseases ◽  
Fecal Calprotectin ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
Irritable Bowel ◽  
Active Disease

Background Determination of fecal calprotectin can provide an important guidance for the physician, also in primary care, in the differential diagnosis of gastrointestinal disorders, meanly between inflammatory bowel diseases and irritable bowel syndrome. Objectives The aims of the present study were to prospectively investigate, in Brazilian adults with gastrointestinal complaints, the value of fecal calprotectin as a biomarker for the differential diagnosis between functional and organic disorders and to correlate the concentrations with the activity of inflammatory bowel diseases. Methods The study included consecutive patients who had gastrointestinal complaints in which the measurement levels of fecal calprotectin were recommended. Fecal calprotectin was measured using a Bühlmann (Basel, Switzerland) ELISA kit Results A total of 279 patients were included in the study, with median age of 39 years (range, 18 to 78 years). After clinical and laboratorial evaluation and considering the final diagnosis, patients were allocated into the following groups: a) Irritable Bowel Syndrome: 154 patients (102 female and 52 male subjects). b) Inflammatory Bowel Diseases group: 112 patients; 73 with Crohn’s disease; 38 female and 35 male patients; 52.1% (38/73) presented active disease, and 47.9% (35/73) had disease in remission and 39 patients with ulcerative colitis;19 female and 20 male patients; 48.7% (19/39) classified with active disease and 49.3% (20/39) with disease in remission. A significant difference (P<0.001) was observed between the median value of fecal calprotectin in Irritable Bowel Syndrome group that was 50.5 µg/g (IQR=16 - 294 µg/g); 405 µg/g (IQR=29 - 1980 µg/g) in Crohn’s disease patients and 457 µg/g (IQR=25 - 1430 µg/g) in ulcerative colitis patients. No difference was observed between the values found in the patients with Crohn’s disease and ulcerative colitis. Levels of fecal calprotectin were significantly lower in patients with inflammatory bowel diseases in remission when compared with active disease (P<0.001). Conclusions The present study showed that the determination of fecal calprotectin assists to differentiate between active and inactive inflammatory bowel diseases and between inflammatory bowel diseases and irritable bowel syndrome.

scholarly journals Setting up a Virtual Calprotectin Clinic in Inflammatory Bowel Diseases: Literature Review and Nancy Experience

2020 ◽  
Vol 9 (9) ◽  
pp. 2697
Author(s):  
Ferdinando D’Amico ◽  
Patrick Netter ◽  
Cedric Baumann ◽  
Muriel Veltin ◽  
Camille Zallot ◽  
...  
Keyword(s):  
Inflammatory Bowel Diseases ◽  
Recent Literature ◽  
Fecal Calprotectin ◽  
University Hospital ◽  
Treat To Target ◽  
Adherence Rate ◽  
Patient’S Satisfaction ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
Home Tests

Technological progress, including virtual clinics, web or smartphone-based applications, and assessment of fecal calprotectin (FC) at home has favored the implementation of treat to target strategies for patients with inflammatory bowel diseases (IBD). Although these innovations are promising and have been associated with a significant reduction in health costs, their application in clinical practice is limited. Here, we summarize the most recent literature on virtual clinics and available FC home tests. In addition, we report the experience of IBD patients monitored through the IBDoc® test at the Nancy University Hospital, focusing on usability testing and patient’s satisfaction. This pilot experience shows that a virtual calprotectin clinic doubles adherence rate to FC in IBD patients. This finding is especially clinically relevant in the post-coronavirus disease 2019 (COVID-19) pandemic era, with an increasing use of e-health.

Fecal calprotectin levels and degree of inflammation in inflammatory bowel diseases patients

2019 ◽  
Vol 493 ◽  
pp. S359-S360
Author(s):  
M. Yordanova ◽  
D. Gerova ◽  
A. Atanasova ◽  
B. Galunska-Kalcheva
Keyword(s):  
Inflammatory Bowel Diseases ◽  
Fecal Calprotectin ◽  
Bowel Diseases ◽  
Inflammatory Bowel

Fecal calprotectin in predicting relapse of inflammatory bowel diseases: A meta-analysis of prospective studies

2012 ◽  
Vol 18 (10) ◽  
pp. 1894-1899 ◽  
Author(s):  
Ren Mao ◽  
Ying-lian Xiao ◽  
Xiang Gao ◽  
Bai-li Chen ◽  
Yao He ◽  
...  
Keyword(s):  
Prospective Studies ◽  
Inflammatory Bowel Diseases ◽  
Meta Analysis ◽  
Fecal Calprotectin ◽  
Bowel Diseases ◽  
Inflammatory Bowel

Tu1941 Fecal Metalloprotease 9 Is a Reliable Biomarker Compared to Fecal Calprotectin in Detecting Endoscopic Activity in Patients With Inflammatory Bowel Diseases

2016 ◽  
Vol 150 (4) ◽  
pp. S984-S985
Author(s):  
Anthony Buisson ◽  
Emilie Vazeille ◽  
Regine Minet-Quinard ◽  
Marion Goutte ◽  
Damien Bouvier ◽  
...  
Keyword(s):  
Inflammatory Bowel Diseases ◽  
Fecal Calprotectin ◽  
Bowel Diseases ◽  
Inflammatory Bowel

Rapid fecal calprotectin correlates with clinical and endoscopic severity of inflammatory bowel diseases

2013 ◽  
Vol 48 (11) ◽  
pp. 1359-1360 ◽  
Author(s):  
Antonio Tursi ◽  
Walter Elisei ◽  
GianMarco Giorgetti ◽  
Marcello Picchio ◽  
Giovanni Brandimarte
Keyword(s):  
Inflammatory Bowel Diseases ◽  
Fecal Calprotectin ◽  
Bowel Diseases ◽  
Inflammatory Bowel

Clinical utility of fecal calprotectin in monitoring disease activity and predicting relapse in pregnant patients with inflammatory bowel diseases

2020 ◽  
Vol 77 ◽  
pp. 105-110
Author(s):  
Amihai Rottenstreich ◽  
Tali Mishael ◽  
Sorina Grisaru Granovsky ◽  
Benjamin Koslowsky ◽  
Hagai Schweistein ◽  
...  
Keyword(s):  
Disease Activity ◽  
Inflammatory Bowel Diseases ◽  
Clinical Utility ◽  
Fecal Calprotectin ◽  
Bowel Diseases ◽  
Inflammatory Bowel

Fecal calprotectin in inflammatory bowel diseases: update and perspectives

2017 ◽  
Vol 55 (4) ◽  
Author(s):  
Hana Manceau ◽  
Valérie Chicha-Cattoir ◽  
Hervé Puy ◽  
Katell Peoc’h
Keyword(s):  
Inflammatory Bowel Diseases ◽  
Therapeutic Response ◽  
Fecal Calprotectin ◽  
Intestinal Wall ◽  
Therapeutic Monitoring ◽  
Non Invasive ◽  
Bowel Diseases ◽  
Calprotectin Level ◽  
Inflammatory Bowel

AbstractInflammatory bowel diseases (IBDs) are chronic diseases that result from the inflammation of the intestinal wall, suspected in any patient presenting with intestinal symptoms. Until recently, the diagnosis was mainly based on both clinical and endoscopic arguments. The use of an easy, fast, reliable, non-invasive, and inexpensive biological assay is mandatory not only in diagnosis but also in evolutionary and therapeutic monitoring. To date, the fecal calprotectin is the most documented in this perspective. This marker allows the discrimination between functional and organic bowel processes with good performance. The determination of the fecal calprotectin level contributes to the evaluation of the degree of disease activity and to monitoring of therapeutic response.

Su1244 Accuracy of Fecal M2-Pyruvate Kinase Compared With Fecal Calprotectin to Assess Endoscopic Severity in Patients With Inflammatory Bowel Diseases

2015 ◽  
Vol 148 (4) ◽  
pp. S-450
Author(s):  
Gilles Boschetti ◽  
Sarah Boyer ◽  
Marion Chauvenet ◽  
Karine Stroeymeyt ◽  
Nicolas Benech ◽  
...  
Keyword(s):  
Pyruvate Kinase ◽  
Inflammatory Bowel Diseases ◽  
Fecal Calprotectin ◽  
Bowel Diseases ◽  
Inflammatory Bowel

scholarly journals POS1008 THE ROLE OF SERUM CALPROTECTIN IN THE DIAGNOSIS OF INFLAMMATORY BOWEL DISEASE IN PATIENTS WITH ANKYLOSING SPONDYLITIS

2021 ◽  
Vol 80 (Suppl 1) ◽  
pp. 772-772
Author(s):  
P. Kulakova ◽  
G. Lukina ◽  
E. Alexandrova ◽  
A. Novikov ◽  
A. Klimets ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Longitudinal Study ◽  
Ankylosing Spondylitis ◽  
Disease Activity ◽  
Inflammatory Bowel Diseases ◽  
Bowel Disease ◽  
Fecal Calprotectin ◽  
Bowel Diseases ◽  
Inflammatory Bowel

Background:Аnkylosing spondylitis (AS) and inflammatory bowel diseases (IBD) have many common features. Approximately one in two patients with axial spondyloarthritis have subclinical (histologically confirmed) inflammation of the intestine, and 5-10% of subclinical inflammation turns into Crohn’s disease (CD) or Ulcerative colitis (UC) [1]. Colonoscopy is usually used to diagnose IBD, but this procedure is invasive. Laboratory biomarkers, as fecal calprotectin (FC) and serum calprotectin (SC) can used to diagnosis of IBD. But there is no consensus regarding SC clinical utility. SC is exposed to proteolytic enzymes, but its level also increases with inflammation in the intestine and is associated with a higher disease activity [2]. SC levels positively correlate with CRP, ESR, disease activity in AS, but not as obvious as with FC [3,4].Objectives:The aim of this study was to evaluate the possibility of using SC in the diagnosis of IBD in patients with AS.Methods:In the analysis were included 50 patients with AS, fulfilling the modified New York criteria, among them man -36 (72%), woman -14 (28%), mean age of patients was 42.5 ±9.9, mean disease duration – 13.4±8.7 years. All patients were examined with ESR, CRP, FC (range: 100-1800 µg /g), esophagogastroduodenoscopy, colonoscopy and quantitative analysis of the SC level using ELISA (BUHLMANN MRP8/14 ELISA, range: 0.4-3.9 µg /ml).Results:All patients had a high disease activity, mean BASDAI was 5.3 ± 1.8, mean ASDAS CRP 3.7 ± 1.01, mean ASDAS ESR 3.6 ± 1.01. 80 % patients had high FC level (more than 100 µg / g), while only 18% patients had an increase of SC level. IBD were diagnosed in 11 cases: 6 patients (12 %) with CD and 5 patients (10 %) - UC, in the remaining cases (78%) was no intestinal pathology. Only 2 patients with IBD had a high SC level. SC level was more correlated with ESR (r=0.5) and CRP (r=0.5) (p <0.05) levels, than with FC level (r=0.4) (p <0.05).Conclusion:The results showed that there is currently insufficient data to assess the possibility of using SC in the diagnosis of IBD in patients with AS. There is a significant association between the SC, CRP and ESR, but not fecal calprotectin. Potentially SC may be more representative of systemic inflammation than an intestinal inflammation.References:[1]Klingberg, E., Strid, H., Stahl, A.et al. A longitudinal study of fecal calprotectin and the development of inflammatory bowel disease in ankylosing spondylitis. A longitudinal study of fecal calprotectin and the development of inflammatory bowel disease in ankylosing spondylitis. Arthritis Res Ther 2017. 19(1):21[2]Kalla R, Kennedy NA, Ventham NT, Boyapati RK, Adams AT, Nimmo ER, Visconti MR, Drummond H, Ho GT, Pattenden RJ, Wilson DC, Satsangi J. Serum Calprotectin: A Novel Diagnostic and Prognostic Marker in Inflammatory Bowel Diseases. Am J Gastroenterol. 2016 Dec;111(12):1796-1805[3]Hu H, Du F, Zhang S, Zhang W. Serum calprotectin correlates with risk and disease severity of ankylosing spondylitis and its change during first month might predict favorable response to treatment. Mod Rheumatol. 2019 Sep;29(5):836-842.[4]Azramezani Kopi T, Shahrokh S, Mirzaei S, Asadzadeh Aghdaei H, Amini Kadijani A. The role of serum calprotectin as a novel biomarker in inflammatory bowel diseases: a review study. Gastroenterol Hepatol Bed Bench. 2019;12(3):183-189.Disclosure of Interests:None declared.

Sign in / Sign up

Export Citation Format

Share Document